Pfizer Corporation

Jonathan Richard Lillis

Timothy Michael Lukas

W James Huang

Kevin Richard Back

Michael Cram

Aidan James Harper

Sumit Luthra

Robert Steven Kania

Robert Louis Hoffman

Dafydd Rhys Owen

Jamison Bryce Tuttle

Matthew Forrest Sammons

Suman Luthra

Samir Kulkarni

Anil Mahadeo Rane

Klimentina Dimitrova Pencheva

Martyn David Ticehurst

Matthew Nathan O'Brien Laramy

Bradley Paul Sullivan

Andrew John Thiel

Padmavani Bezawada

Rohit Jaini

Emma Louise Hawking

The invention relates to compounds of formula I wherein R, Rand - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Compounds and methods for the treatment of COVID-19

The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Formulations of a PI3K/mTOR-inhibitor for intravenous administration

The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Formulations of a PI3K/mTor-inhibitor for intravenous administration

Growing community of inventors

Sandwich, United Kingdom

Jonathan Richard Lillis